TCR² Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry Conference
30 août 2019 08h00 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
TCR² Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
08 août 2019 06h45 HE
|
TCR2 Therapeutics
Began dosing of TC-210 in the Phase 1/2 trial for patients with mesothelin-expressing solid tumors and an interim update anticipated in 4Q19/1Q20Leading clinical sites participating in the TC-210...
TCR² Therapeutics to Participate in Upcoming Conferences in August
06 août 2019 16h05 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
TCR2 Therapeutics Deepens Manufacturing and Immuno-Oncology Expertise with Key Hires
06 août 2019 06h45 HE
|
TCR2 Therapeutics
Expansion of leadership team to support clinical trials with an emphasis on manufacturing, IND enablement and development of next generation of TRuC-T cells CAMBRIDGE, Mass., Aug. 06, 2019 (GLOBE...
TCR2 Therapeutics Announces Partnership with the National Cancer Institute for Phase 1/2 Trial of TC-210
31 juil. 2019 06h45 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
TCR2 Therapeutics Added to Russell 2000®, 3000® and Microcap® Indexes
28 juin 2019 08h00 HE
|
TCR2 Therapeutics
CAMBRIDGE, Mass., June 28, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company developing the next generation of novel T cell therapies for...
TCR2 Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
13 mai 2019 16h05 HE
|
TCR2 Therapeutics
Initiated Phase 1/2 clinical trial for TC-210, TCR2’s lead product candidate targeting mesothelin expressing solid tumorsOn track to file an IND for TCR2’s lead hematology product candidate, TC-110,...
TCR2 Therapeutics Publishes First Peer-Reviewed Data Demonstrating Superior Anti-Tumor Activity of the Company’s Novel TRuC™-T Cells
07 mai 2019 05h00 HE
|
TCR2 Therapeutics
Preclinical study results published in Nature Communications show superior anti-tumor activity of T cell receptor fusion construct T cells (TRuC™)-T cells compared to chimeric antigen receptor (CAR)-T...
TCR2 Therapeutics Announces First Quarter 2019 Earnings Conference Call and Webcast
29 avr. 2019 16h30 HE
|
TCR2 Therapeutics
Earnings to be released after market close on Monday, May 13, 2019 CAMBRIDGE, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (TCR2) (Nasdaq: TCRR), a clinical-stage immunotherapy...